Literature DB >> 20018390

Current status and challenges of antiretroviral research and therapy.

José A Esté1, Tomas Cihlar.   

Abstract

Twenty-five years after the discovery of the therapeutic activity of azidothymidine (AZT), the first antiretroviral drug used in the clinic, infection with the human immunodeficiency virus (HIV) has become, at least in the industrialized world, a manageable chronic disease with a significant improvement in life expectancy and quality. Nevertheless, the number of new infections worldwide continues to rise, particularly in women, and effective drug treatments have not yet reached the vast majority of infected individuals in resource-limited countries. The current status of antiretroviral therapy is therefore encouraging, but significant challenges remain. Although highly active antiretroviral therapy (HAART) provides durable control of virus replication in many patients, it is not devoid of unwanted secondary effects, some of which are now surfacing in aging populations under long-term treatment. The emergence of multidrug resistance and transmission of drug-resistant HIV strains limit the clinical efficacy of current therapy. Further simplification of treatment and identification of more effective drug combinations are needed to improve patient adherence, the most significant cause of treatment failure. Finding new drugs and novel drug targets may lead to redefining the goals of antiretroviral therapy, with an attempt to achieve the ultimate objective: the eradication of infection. Preclinical and clinical biomedical research, rational drug design and a close collaboration with regulatory agencies to set standards for the transition of new treatment concepts into the clinic will be the cornerstones of future progress. This special issue of Antiviral Research [85(1), 2010] highlights the principal milestones of antiretroviral research over 25 years of drug discovery and development and offers a comprehensive analysis by leading experts of the efforts being made to meet the challenges of effective control of HIV infection. This article forms part of a special issue of Antiviral Research marking the 25th anniversary of antiretroviral drug discovery and development, vol. 85, issue 1, 2010. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20018390     DOI: 10.1016/j.antiviral.2009.10.007

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  81 in total

Review 1.  Progress in the development of new therapies for herpesvirus infections.

Authors:  Nathan B Price; Mark N Prichard
Journal:  Curr Opin Virol       Date:  2011-12       Impact factor: 7.090

Review 2.  Translational research in behavior analysis: historical traditions and imperative for the future.

Authors:  F Charles Mace; Thomas S Critchfield
Journal:  J Exp Anal Behav       Date:  2010-05       Impact factor: 2.468

Review 3.  Emerging reverse transcriptase inhibitors for HIV-1 infection.

Authors:  Mohammad A Rai; Sam Pannek; Carl J Fichtenbaum
Journal:  Expert Opin Emerg Drugs       Date:  2018-05-10       Impact factor: 4.191

4.  Macrophage endocytic trafficking of antiretroviral nanoparticles.

Authors:  Irena Kadiu; Ari Nowacek; Joellyn McMillan; Howard E Gendelman
Journal:  Nanomedicine (Lond)       Date:  2011-03-21       Impact factor: 5.307

5.  Liposomes as nanocarriers for anti-HIV therapy.

Authors:  Shruti Chopra; Natarajan Venkatesan; Guru V Betageri
Journal:  Drug Deliv Transl Res       Date:  2013-10       Impact factor: 4.617

Review 6.  The role of nanotechnology in the treatment of viral infections.

Authors:  Lavanya Singh; Hendrik G Kruger; Glenn E M Maguire; Thavendran Govender; Raveen Parboosing
Journal:  Ther Adv Infect Dis       Date:  2017-07-05

7.  "So far it's been choosing which side effects I want or I can deal with": A grounded theory of HIV treatment side effects among people living with HIV.

Authors:  Marilou Gagnon; Dave Holmes
Journal:  Aporia       Date:  2016-01-01

8.  Tautomerism provides a molecular explanation for the mutagenic properties of the anti-HIV nucleoside 5-aza-5,6-dihydro-2'-deoxycytidine.

Authors:  Deyu Li; Bogdan I Fedeles; Vipender Singh; Chunte Sam Peng; Katherine J Silvestre; Allison K Simi; Jeffrey H Simpson; Andrei Tokmakoff; John M Essigmann
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-28       Impact factor: 11.205

9.  Laser ablation for pharmaceutical nanoformulations: Multi-drug nanoencapsulation and theranostics for HIV.

Authors:  Ajay Singh; Hilliard L Kutscher; Julia C Bulmahn; Supriya D Mahajan; Guang S He; Paras N Prasad
Journal:  Nanomedicine       Date:  2020-02-13       Impact factor: 5.307

10.  A tonsillar PolyICLC/AT-2 SIV therapeutic vaccine maintains low viremia following antiretroviral therapy cessation.

Authors:  Panagiotis Vagenas; Meropi Aravantinou; Vennansha G Williams; Edith Jasny; Michael Piatak; Jeffrey D Lifson; Andres M Salazar; James L Blanchard; Agegnehu Gettie; Melissa Robbiani
Journal:  PLoS One       Date:  2010-09-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.